FDA to review Arpida's NDA for iclaprim

Arpida, a Swiss biopharmaceutical company that focuses on the discovery, development and commercialization of novel products for the treatment of microbial infections, has received notice from the US Food and Drug Administration that the agency's Anti-Infective Drugs Advisory Committee will discuss the New Drug Application for intravenous iclaprim in complicated skin and skin structure infections during its meeting on November 18-20.

Iclaprim is a hospital antibiotic drug candidate with potent bactericidal activity against methcillin-resistant Staphylococcus aureus and an extended range of important pathogens. Arpida has also filed marketing applications in Canada and Europe.

Paul Hadvary, head of development at Arpida, said: "we are delighted to have an opportunity to present iclaprim to leading experts in the anti-infective field and to discuss important features of our NDA with the Advisory Committee."